Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

55.44
+0.12000.22%
Post-market: 55.720.2800+0.51%18:35 EDT
Volume:1.06M
Turnover:58.94M
Market Cap:5.36B
PE:-11.65
High:56.59
Open:55.45
Low:54.82
Close:55.32
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:0.80
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:3.07
PE(LYR):-8.57

Loading ...

Shareholders Approve New Incentive Plan and Governance Measures

TIPRANKS
·
Jun 05

CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Jun 04

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial

TIPRANKS
·
May 23

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
May 14

A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest

Simply Wall St.
·
May 12

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

TIPRANKS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83

TIPRANKS
·
May 05

CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated

TIPRANKS
·
May 05

CRISPR Therapeutics Ag : Bofa Global Research Cuts Price Objective to $83.00 From $86.00

THOMSON REUTERS
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeneDx Holdings (WGS) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Switzerland's CRISPR Therapeutics Q1 net loss narrows

Reuters
·
May 05

CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate

Benzinga Earnings
·
May 05